263 related articles for article (PubMed ID: 15527223)
1. [Pancreatic carcinoma: progress in therapy].
Lordick F
Krankenpfl J; 2004; 42(5-6):158-9. PubMed ID: 15527223
[No Abstract] [Full Text] [Related]
2. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
[TBL] [Abstract][Full Text] [Related]
3. [Chemotherapy of pancreatic carcinoma].
Lutz MP
Praxis (Bern 1994); 2005 Jun; 94(22):933-5. PubMed ID: 15986638
[TBL] [Abstract][Full Text] [Related]
4. Palliative chemotherapy for pancreatic malignancies.
Mehta SP
Surg Clin North Am; 2010 Apr; 90(2):365-75. PubMed ID: 20362792
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs in pancreatic cancer.
Ducreux M; Boige V; Malka D
Expert Opin Emerg Drugs; 2004 May; 9(1):73-89. PubMed ID: 15155137
[TBL] [Abstract][Full Text] [Related]
6. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine doublets in advanced pancreatic cancer: should we move on?
Rocha Lima CM; Flores AM
J Clin Oncol; 2006 Jan; 24(3):327-9. PubMed ID: 16344312
[No Abstract] [Full Text] [Related]
8. [Gemcitabine-based combinations in inoperable pancreatic cancers].
Louvet C; André T; Artru P
Bull Cancer; 2002 Aug; 89 Spec No():S96-101. PubMed ID: 12449038
[TBL] [Abstract][Full Text] [Related]
9. [Non-surgical treatment for pancreatic cancer].
Okusaka T; Ueno H; Ikeda M; Morizane C
Nihon Shokakibyo Gakkai Zasshi; 2006 Apr; 103(4):391-7. PubMed ID: 16629457
[No Abstract] [Full Text] [Related]
10. [Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma].
Boxberger F; Happich K; Schirner I; Brueckl WM; Hohenberger W; Hahn EG; Wein A
Z Gastroenterol; 2002 Oct; 40(10):881-4. PubMed ID: 12436355
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of randomized trials: evaluation of benefit of gemcitabine-based molecular targeted therapy for inoperable pancreatic cancer.
Cao Y; Wu L; Tan A; Liu L; Liao C; Gao F
Pancreas; 2010 Mar; 39(2):253-5. PubMed ID: 20182311
[No Abstract] [Full Text] [Related]
12. Complete remission of metastatic pancreatic cancer with cardiac involvement after gemcitabine, oxaliplatin and 46-h infusion of 5-fluorouracil/leucovorin.
Wu WC; Chen SC; Su YC; Chuang WL; Chen LT
J Gastroenterol Hepatol; 2004 Jun; 19(6):716-7. PubMed ID: 15151634
[No Abstract] [Full Text] [Related]
13. Recent updates on the role of chemotherapy in pancreatic cancer.
Burris HA
Semin Oncol; 2005 Aug; 32(4 Suppl 6):S1-3. PubMed ID: 16143160
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy for advanced pancreatic cancer--has its time finally come?
Kulke MH
Lancet Oncol; 2005 Jun; 6(6):352-3. PubMed ID: 15948320
[No Abstract] [Full Text] [Related]
15. Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
Hess V; Pratsch S; Potthast S; Lee L; Winterhalder R; Widmer L; Cescato C; Lohri A; Jost L; Stillhart P; Pestalozzi B; Herrmann R
Ann Oncol; 2010 Dec; 21(12):2390-2395. PubMed ID: 20444846
[TBL] [Abstract][Full Text] [Related]
16. Conventional chemotherapy of advanced pancreatic cancer.
Giuliani F; Di Maio M; Colucci G; Perrone F
Curr Drug Targets; 2012 Jun; 13(6):795-801. PubMed ID: 22458526
[TBL] [Abstract][Full Text] [Related]
17. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced carcinoma of the pancreas.
Oztop I; Yilmaz U; Yavuzsen T; Yaren A; Tarhan O; Sagol O; Coker A; Alakavuklar M
Chemotherapy; 2004 Jun; 50(3):127-32. PubMed ID: 15282439
[TBL] [Abstract][Full Text] [Related]
19. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Yoo C; Hwang JY; Kim JE; Kim TW; Lee JS; Park DH; Lee SS; Seo DW; Lee SK; Kim MH; Han DJ; Kim SC; Lee JL
Br J Cancer; 2009 Nov; 101(10):1658-63. PubMed ID: 19826418
[TBL] [Abstract][Full Text] [Related]
20. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]